MIMS invites applications for a Group Leader position at Umeå University, Sweden
MIMS - The Laboratory for Molecular Infection Medicine Sweden is the Swedish node of the Nordic EMBL Partnership for Molecular Medicine and hosted at Umeå University in Northern Sweden. MIMS now invites applications from outstanding candidates within molecular infection medicine.
Excellent research environment to spark new ideas.
MIMS performs basic and translational research in molecular infection medicine and is the home of the CRISP/Cas9 discovery, a technology that eventually led to the Nobel Prize in Chemistry in 2020. Major achievements in infection research covering the full range of viral, bacterial and eukaryotic pathogens. MIMS offers an exceptional environment for research into bacterial pathogenesis and parasite cell biology. A vibrant community of virologists and clinical research units are associated with the local university hospital. Researchers with an interest in the structural basis of infection will find an outstanding and highly accessible facility for cryo-electron microscopy. The vibrant life science activities in Northern Sweden include growing research and startup activities. Group Leaders are expected to introduce novel topics and tools, to strengthen synergies of ongoing MIMS research, and to build a programme at the international level that can also support interdisciplinary and translational collaborations.
Group Leader positions with attractive start-up packages and EMBL association.
MIMS seeks candidates with promising original research programmes for the position as Group Leaders with an initial 5-year appointment and the opportunity for a 4-year extension following the EMBL model. MIMS Group Leader positions come with an attractive start-up package, access to state-of-the-art facilities and infrastructure and ample opportunities to engage with a wide and inspiring international research community, especially with the European Molecular Biology Laboratory (EMBL) and the Nordic EMBL Partnership for Molecular Medicine. The new Group Leader receives mentoring from both local and international capacities.
The Nordic EMBL Partnership for Molecular Medicine is a joint venture between EMBL and the universities of Helsinki/Finland, Oslo/Norway, Umeå/Sweden, and Aarhus/Denmark. The Partnership provides joint access to research infrastructures, including databases, facilities, and instrumentation, as well as to clinical materials, networks, and training activities. The Nordic countries offer excellent conditions for research, equal opportunities, and quality of life.
Read further and apply via Umeå University’s e-recruitment system: https://umu.varbi.com/en/what:job/jobID:620573/
Deadline: July 31st 2023, 23:59 CEST
Contact information: Prof. Oliver Billker, Director, phone: +46 90 785 6778, email@example.com